Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S. 2 years ago [#item_full_content] Dr. Reddy’s Laboratories Announces First-to-Market Launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe in the U.S. MarketDateMarch 19, 2020In relation toSimilar postTeva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tabletsDateMay 17, 2021In relation toSimilar postTeva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of RosaceaDateJune 16, 2021In relation toSimilar post
